Ambronaaf15 mg/5 ml

Established use

Ambronaaf is indicated as a mucolytic/expectorant for the symptomatic treatment of acute and chronic respiratory disorders associated with excessive, viscous mucus, including:

• Acute bronchitis
• Chronic bronchitis, including acute exacerbations
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD) with productive cough, as an adjunct to standard therapy

Adjunct / lower-evidence use

In some markets, Ambronaaf lozenge or spray formulations are used for symptomatic relief of sore throat. This is a secondary use with a lower strength of evidence than its mucolytic indication.

Ambronaaf treats the symptom of thick mucus; it does not treat an underlying bacterial infection and is not a substitute for antibiotics when a bacterial infection is present.

Ambroxol Hydrochloride is available in several dosage forms and strengths for different age groups:

• Tablets: 30 mg Ambroxol Hydrochloride
• Sustained-release capsules: 75 mg Ambroxol Hydrochloride
• Syrup: 15 mg/5 mL Ambroxol Hydrochloride
• Pediatric drops: 6 mg/mL Ambroxol Hydrochloride

Each formulation also contains standard pharmaceutical excipients (e.g. preservatives, sweeteners, flavoring agents); exact excipients vary by manufacturer and brand.

Ambronaaf is a mucoactive (mucolytic) agent and the major active metabolite of bromhexine. It is used to help clear thick, sticky mucus from the airways in respiratory conditions accompanied by a productive cough, working by breaking down mucus fibers and supporting the lung's natural clearance mechanisms so that cough becomes more productive and less effortful.

Ambronaaf is widely marketed in Bangladesh and internationally as tablets, sustained-release capsules, syrup, and pediatric drops. While available without a prescription in many markets, medical advice is recommended before use, particularly for infants, pregnant or breastfeeding women, and patients with chronic liver, kidney, or gastric conditions.

Ambronaaf belongs to the therapeutic class of Mucolytics / Expectorants, medicines used to reduce the viscosity of respiratory secretions and facilitate their clearance from the airway.

Ambroxol Hydrochloride is the principal active metabolite of bromhexine. It produces a mucolytic (secretolytic) effect by depolymerizing acid mucopolysaccharide fibers within bronchial mucus, reducing sputum viscosity. It also stimulates surfactant synthesis and release from type II pneumocytes, which improves mucociliary clearance and reduces mucus adherence to the bronchial wall. Laboratory studies also suggest mild anti-inflammatory and antioxidant properties, and a local anesthetic-like action that underlies the use of Ambroxol Hydrochloride in some throat lozenge formulations.

Onset of action typically begins within about 30 minutes of oral administration, with a noticeable clinical effect on sputum viscosity generally apparent within 1-2 days of regular use. Ambroxol Hydrochloride is well absorbed orally, extensively metabolized in the liver, and eliminated mainly via the kidneys, with a plasma elimination half-life of approximately 7-12 hours (longer with sustained-release formulations).

Ambronaaf tablets and sustained-release capsules should be swallowed whole with a glass of water and should not be crushed or chewed. Syrup and pediatric drops should be measured accurately using the measuring cup or dropper supplied with the product, and the bottle should be shaken well before use. Ambronaaf can be taken with or without food, though taking it after meals may help minimize gastrointestinal discomfort. Adequate fluid intake is recommended while taking Ambronaaf, as this supports its mucolytic effect.

Ambronaaf has a low potential for clinically significant drug interactions. Notable considerations include:

• Antibiotics (e.g. amoxicillin, cefuroxime, erythromycin, doxycycline): Ambronaaf has been reported to increase the penetration of certain antibiotics into bronchial secretions and lung tissue; this is generally considered a beneficial interaction rather than a safety concern, but should be noted by the prescriber.
• Antitussives / centrally-acting cough suppressants (e.g. codeine, dextromethorphan): Combining Ambronaaf with cough suppressants is generally discouraged, as suppressing the cough reflex can cause dangerous accumulation of loosened mucus in the airway.

No other well-established, clinically significant drug interactions have been documented for Ambronaaf. Patients should inform their physician of all medicines they are taking before starting Ambronaaf.

Most patients tolerate Ambronaaf well. Reported side effects include:

Common

• Nausea
• Mild gastrointestinal discomfort or epigastric pain
• Occasional diarrhea

Uncommon / rare

• Skin rash, urticaria
• Hypersensitivity reactions, including very rare reports of severe skin reactions (e.g. Stevens-Johnson syndrome) with ambroxol-containing products
• Angioedema, dyspnea, and anaphylactic reactions (rare)
• Dry mouth or dry throat

Patients should stop Ambronaaf and seek immediate medical attention if signs of a severe allergic or skin reaction occur.

Ambronaaf should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; conservative practice generally advises avoiding use during the first trimester. Animal reproduction studies have not shown harmful effects, but adequate, well-controlled studies in pregnant women are limited. A physician should always be consulted before using Ambronaaf during pregnancy.

It is not established whether Ambronaaf passes into breast milk in clinically significant amounts. As a precaution, use during breastfeeding should occur only on medical advice, weighing the benefit against any unknown risk to the nursing infant.

Use Ambronaaf with caution in the following situations:

• Patients with a history of peptic ulcer disease, as Ambronaaf may occasionally cause gastric irritation.
• Patients with severe renal or hepatic impairment (see Use in Special Populations).
• Patients with impaired mucociliary function or rare conditions causing abnormally large secretion volumes, since loosened mucus may be difficult to clear.

Discontinue Ambronaaf and consult a physician if cough persists beyond 5-7 days, recurs, or is accompanied by high fever, skin rash, persistent headache, or difficulty breathing, as this may indicate a condition requiring different treatment. Stop immediately and seek medical care if any sign of a skin or hypersensitivity reaction develops (see Side Effects). Ambronaaf should not be combined with cough suppressants (see Interaction).

Overdose with Ambronaaf is generally expected to cause, at most, transient gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), restlessness, or drooling, based on available data. In case of a known or suspected overdose of Ambronaaf, seek immediate medical attention or contact a poison control center or emergency services; do not attempt to manage a suspected overdose at home. Treatment is generally supportive and symptomatic.

Store Ambronaaf at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Ambronaaf and its metabolites are eliminated mainly via the kidneys; in patients with severe renal impairment, elimination may be reduced, and dose reduction or extended dosing intervals should be considered under medical supervision.

Hepatic impairment

Ambronaaf is extensively metabolized in the liver; patients with severe hepatic impairment may have reduced clearance, and lower doses or closer monitoring are advised.

Elderly

No specific dose adjustment is generally required for Ambronaaf in elderly patients, but age-related decline in renal or hepatic function should be considered.

Children

See Pediatric Uses and Dosage and Administration for age-appropriate dosing of Ambronaaf.

Ambronaaf is generally intended for short-term symptomatic use. If cough or respiratory symptoms do not improve within 5-7 days of starting Ambronaaf, or if they worsen, medical review is recommended, as this may indicate an underlying condition needing separate treatment (e.g. a bacterial infection). For chronic bronchitis or COPD, a physician may prescribe Ambronaaf for longer, intermittent courses as part of overall disease management.

Ambroxol Hydrochloride is classified as a Mucolytic Agent / Expectorant, and is the major active metabolite of the related mucolytic agent bromhexine.

Ambroxol Hydrochloride reduces the viscosity of mucus by breaking down acidic mucopolysaccharide fibers within bronchial secretions and by stimulating the production and release of pulmonary surfactant from alveolar type II cells. This dual action loosens thick mucus and improves mucociliary transport, making cough more effective at clearing the airway.

Use of Ambronaaf in children should follow age-appropriate, weight-based dosing under medical guidance:

• Infants under 6 months: use of Ambronaaf is generally reserved for situations where a physician determines it is clearly needed, given limited safety data in this age group; strict medical supervision is advised.
• Infants 6 months to 2 years: pediatric drop formulation, low dose, twice daily (see Dosage and Administration).
• Children 2-12 years: syrup formulation, age-based dose, 2-3 times daily.
• Children over 12 years: adult dosing may apply, including sustained-release capsules.

Safety and efficacy of Ambronaaf sustained-release capsules have not been established in children under 12 years; the syrup or pediatric drop formulations should be used instead. Parents and caregivers should not exceed the recommended dose of Ambronaaf and should consult a pediatrician for infants and for symptoms lasting more than a few days.